Professor Shankar Siva of Peter MacCallum Cancer Centre joins the show to discuss the emerging role of stereotactic body radiotherapy in primary and metastatic RCC tumors. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
Dr. Dorff reviews expectations for GU oncology updates in 2025.
Dr. Silke Gillessen is joined by special guests to discuss the top highlights from 2024 in the prostate cancer field.
Dr. Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer from 2024.
Dr. David McDermott joins the podcast to review the top data from 2024 in the renal cell carcinoma field.
Dr. Jim Brugarolas joins the podcast to discuss his talk from IKCS 2024 and the broad topic of resistance to HIF inhibitors.
Dan Suzman, Deputy Oncology Director of the FDA, joins the podcast to discuss the Accelerated Approval process.
Advertisement
The Uromigos: Live and Unplugged 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Kidney Cancer Discussions
Dr. David McDermott joins the podcast to review the top data from 2024 in the renal cell carcinoma field.
Dr. Jim Brugarolas joins the podcast to discuss his talk from IKCS 2024 and the broad topic of resistance to HIF inhibitors.
Dr. Andrew Smith, chair of diagnostic imaging at St. Jude's, joins the podcast to discuss the emerging field of radiomics.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.